# Table of Contents

<table>
<thead>
<tr>
<th>Foreword</th>
<th>xxv</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preface</td>
<td>xxvii</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>xxix</td>
</tr>
<tr>
<td>Abbreviations</td>
<td>xxxi</td>
</tr>
<tr>
<td>Advisory Board</td>
<td>xxxix</td>
</tr>
<tr>
<td>Contributors</td>
<td>xli</td>
</tr>
</tbody>
</table>

## PART I GENOMIC APPROACHES TO BIOLOGY AND MEDICINE

---

### Section 1 Principles of Human Genomics 3

1. Organization, Variation and Expression of the Human Genome as a Foundation of Genomic and Personalized Medicine
   **Huntington F. Willard**
   - Introduction 4
   - The Human Genome 6
   - Variation in the Human Genome 9
   - Expression of the Human Genome 11
   - Genes, Genomes and Disease 13
   - From Genome to Personalized Medicine 15
   - Conclusion 18
   - References 18
   - Recommended Resources 21

2. Concepts of Population Genomics 22
   **Mike E. Weale and David B. Goldstein**
   - Introduction 22
   - Important Concepts in Population Genomics 22
   - Human Population Genomics 26
   - Application of Population Genomics to Genomic Medicine 28
   - Conclusions 29
   - References 30
   - Recommended Resources 32

3. Genomic Approaches to Complex Disease 33
   **Desmond J. Smith and Aldons J. Lusis**
   - Introduction 33
   - Identifying Common and Rare Genomic Variations in the Population 33
   - Relating DNA Variation to Phenotypes 36
   - Integration of “Omic” Technologies with Genetics 40
   - Conclusions and Prospects 43
   - Acknowledgements 43
   - References 43
   - Recommended Resources 46

---

4. Human Health and Disease: Interaction Between the Genome and the Environment 47
   **Kenneth Olden**
   - Introduction 47
   - Importance of the Environment 48
   - The Environmental Genome Project 50
   - Problematic Nature of Gene–environment Interaction Studies 52
   - Polymorphism and Disease Susceptibility: Case–control Studies 53
   - Epigenetics and the Environment 56
   - Conclusion 57
   - Acknowledgements 57
   - References 57

5. Epigenomics and its Implications for Medicine 60
   **Moshe Szyf**
   - Introduction 60
   - DNA Methylation Patterns 61
   - Chromatin Modification 63
   - DNA Methylation and Chromatin States Co-operatively Determine the State of Activity of Genes 65
   - Epigenetics and Human Disease 67
   - Conclusions 69
   - Acknowledgements 70
   - References 70

6. Systems Biology and the Emergence of Systems Medicine 74
   **Nathan D. Price, Lucas B. Edelman, Inyoul Lee, Hyuntae Yoo, Dahee Huang, George Carlson, David J. Galas, James R. Heath and Leroy Hood**
   - Introduction 74
   - Systems Science in Biology And Medicine 75
   - Multi-parameter Blood-bourne Biomarkers 76
   - Emerging in vivo and in vitro Technologies 78
   - Computational and Mathematical Challenges in Systems Medicine 81
   - Conclusions and Perspectives 81
   - References 82
   - Recommended Resources 85
Section 2 Technology Platforms for Genomic Medicine

7. DNA Sequencing for the Detection of Human Genome Variation and Polymorphism

*Samuel Levy and Yu-Hai Rogers*

- Introduction 88
- DNA Sequencing 89
- Other Methodologies for Polymorphism Detection 95
- Future Directions 96
- Acknowledgements 97
- References 97

8. Genome-Wide Association Studies and Genotyping Technologies

*Kevin V. Shihama*

- Introduction 101
- Principles of Genome-wide Association Studies 101
- Platform Overview 103
- Conclusion 106
- References 106

9. Copy Number Variation and Human Health

*Charles Lee, Courtney Hyland, Arthur S. Lee, Shona Hislop and Chunhua Ihm*

- Introduction 108
- Basic Principles of CNVs 108
- Detecting CNVs in a Genome-wide Manner 112
- Association of CNVs to Disease and Disease Susceptibility 114
- Implications of CNVs 116
- Conclusions 118
- Acknowledgements 118
- References 118
- Recommended Resources 119

10. Inter-Species Comparative Sequence Analysis: A Tool for Genomic Medicine

*Anthony Antonellis and Eric D. Green*

- Introduction 120
- Performing Comparative Sequence Analysis: Resources and Methods 121
- Comparative Sequence Analysis and Human Genetic Disease 124
- CSA and the Future of Human Genetics and Genomic Medicine 128
- References 128
- Recommended Resources 130

11. DNA Methylation Analysis: Providing New Insight into Human Disease

*Susan Cottrell, Theo de Vos, Juergen Distler, Carolina Haefliger, Ralf Lesche, Achim Plum and Matthias Schuster*

- Introduction 131
- Technology to Assess DNA Methylation 132
- Clinical Impact of DNA Methylation Analysis 136
- Conclusion 139
- References 139
- Recommended Resources 142

12. Transcriptomics: Translation of Global Expression Analysis to Genomic Medicine

*Michele M. Kittleson, Rafael Irizarry, Bettina Heidecker and Joshua M. Hare*

- Introduction 143
- Gene Expression Technology 143
- Gene Discovery 146
- Molecular Signature Analysis 148
- Gene Discovery Versus Molecular Signature Analysis 151
- Current Issues in Gene Expression Analysis 151
- Alternative Technologies for Analysis of the Transcriptome 153
- Conclusion 153
- Acknowledgements 154
- References 154
- Recommended Resources 156

13. DNA Microarrays in Biological Discovery and Patient Care

*Andrew J. Yee and Sridhar Ramaswamy*

- Introduction 157
- Microarray Technology 157
- Data Analysis 160
- Applications 161
- Limitations and Challenges 165
- Future Directions 165
- Conclusions 168
- References 168
- Recommended Resources 172

14. Proteomics: The Deciphering of the Functional Genome

*Li-Rong Yu, Nicolas A. Stewart and Timothy D. Veenstra*

- Introduction 173
- Gel-based and Solution-based Proteomics 174
- Mass Spectrometry 175
- Bioinformatics 176
- Impact of Proteomics on Understanding Diseases 178
- Conclusions 178
- Acknowledgements 179
- References 179
- Recommended Resources 179

15. Comprehensive Metabolic Analysis for Understanding of Disease Mechanisms

*Christopher B. Neugard, Robert D. Stevens, Brett R. Wenner, Shawn C. Burgess, Olga Ilkayeva, Michael J. Muehlbauer, A. Dean Sherry and James R. Bain*

- Introduction 180
- Current Metabolomics Platforms: Basic Tools and General Features 181
   Bjorn T. Gjertsen and James B. Lorens

   Introduction 193
   RNA Interference 194
   Gene Function Analysis: An Overview 194
   Chemical Genomics 197
   Gene Function Studies 199
   Conclusions 200
   Acknowledgements 201
   References 201
   Recommended Resources 203

Section 3 Informatic and Computational Platforms for Genomic Medicine 205

17. Bioinformatic and Computational Analysis for Genomic Medicine 206
   Atul J. Butte

   Introduction 206
   Vignettes: How Specific Bioinformatics Methods Can Change the Practice of Medicine 207
   Analytic Methods 213
   Where Data for Studies May Be Found 214
   Bioinformatics Vocabularies and Ontologies 215
   Freely Available Bioinformatics Tools 216
   New Questions for Genomic Medicine 220
   Acknowledgements 221
   References 221
   Recommend Resources 225

18. Fundamentals and History of Informatics for Genomic and Personalized Medicine 226
   A. Jamie Cuticchia

   Introduction 226
   Databases for Genomic Medicine 227
   Conclusion 230
   References 231
   Recommended Resources 232

19. Electronic Medical Records in Genomic Medicine Practice and Research 233
   Glenn S. Gerhard, Robert D. Langer, David J. Carey and Walter F. Stewart

   Introduction 233
   EMRs and Genomic Medicine Clinical Practice 234
   EMRs and Genomic Medicine Research 236
   Conclusion 240
   Acknowledgements 240
   References 240
   Recommended Resources 241

20. Clinical Decision Support in Genomic and Personalized Medicine 242
    Kensaku Kawamoto and David F. Lobach

    Introduction 242
    CDS Background: History, Examples, Evidence of Effectiveness, and Desirable Attributes 243
    Potential Uses of CDS to Support Genomic and Personalized Medicine 245
    Limited Deployability: The Potential Achilles’ Heel of CDS Systems for Genomic Medicine 246
    Challenges to Widespread Deployment of Effective CDS Systems 247
    Conclusions 249
    Disclosures 249
    References 249
    Recommended Resources 251

21. Online Health Information Retrieval by Consumers and the Challenge of Personal Genomics 252
    Mark S. Boguski

    Introduction 252
    Characteristics of Consumer Searches for Health Information 252
    What and Where Are Consumers Searching? 253
    Personalized Genomics for Consumers 255
    Summary and Conclusions 256
    References 256
    Wikipedia References 257

PART II TRANSLATIONAL APPROACHES IN GENOMIC AND PERSONALIZED MEDICINE

Section 4 Enabling Strategies in the Translation of Genomics into Medicine 261

22. Translational Genomics: From Discovery to Clinical Practice 262
    Geoffrey S. Ginsburg

    Introduction 262
    A Roadmap for Translation 263
    Where Can Genomics Have Impact in the Continuum of Health and Disease? 263
    The Genomics “Gold Rush” 264
The Personal Genome: Precious Code or Fool’s Gold? 266
“Grand Challenges” in Translation of Genomics to Human Health 266
Translational Genomics: Enabling Competencies 267
How Are We Going to Do This? Developing Environments That Foster Translational Genomics to Health Applications 270
References 272

23. Principles of Study Design 275
Peter Grass
Introduction 275
Principles of Experimental Design 276
Design Issues in Genomic Medicine 281
References 283
Recommended Resources 283

24. Biobanking in the Post-Genome Era 284
Theresa Puijun Chow, Chia Kee Seng, Per Hall and Edison T. Liu
Introduction 284
The Biobanking Evolution 285
The Past Imperfect Resources 285
The Evolving Face of Biobanking 285
Existing Models: Biobanking in Europe and the USA 286
Singapore’s National Biobank and National Aspirations In Biomedical Research 288
The Future of National Biobanks 294
References 296
Recommended Resources 297

25. Application of Biomarkers in Human Population Studies 299
Stefano Bonassi and Monica Neri
Introduction 299
Biomarkers in Medicine 299
Biomarkers of Exposure 302
Biomarkers of Early Disease Risk 303
Biomarkers of Genetic Susceptibility to Disease 304
Conclusions 306
References 306

26. Validation of Candidate Protein Biomarkers 308
Ingólfur Hilmarsson and Nader Rifai
Introduction 308
Optimization of the Candidate Protein Research Assay 308
Analytical Evaluation 309
Reference Intervals 311
Pre-analytical Variation 311
Clinical Evaluation 312
Indicators of Diagnostic Accuracy And Predictability 313
Diagnostic Research Studies 316
Design of Diagnostic Studies 316
Transferability Of Test Performance 317
Assay Transfer to Diagnostic Company 317
Regulatory Requirements 318
References 318
Recommended Resources 320

27. Pharmacogenetics and Pharmacogenomics 321
Iris Grossman and David B. Goldstein
Introduction 321
Pharmacogenetic Studies: From Concept to Practice 323
Marker Selection – Strategy and Application 325
From Bench to Bedside: Integration of Pharmacogenetic Testing into Clinical Practice 328
Examples of PGx Tests: Promising New Developments and Marketed Products 329
Future Developments Required for the Field to Fully Meet its Expectations 331
References 332
Recommended Resources 334

28. The Role of Genomics and Genetics in Drug Discovery and Development 335
Robert I. Tepper and Ronenn Roubenoff
Introduction 335
The Drug Discovery Process 335
Genomics in Target Discovery 336
Genomic Approaches to Drug Identification 337
Pharmacogenomics and Drug Development 337
Pharmacodynamic Markers and their Role in Drug Discovery and Development 338
Toxicogenomics 340
Genetics and Genomics in Clinical Trial Design 340
Genomics in Drug Approval and Regulation 340
Conclusion 341
References 341
Recommended Resources 342

29. Role of Pharmacogenomics in Drug Development 343
Colin F. Spraggs, Beena T. Koshy, Mark R. Edbrooke and Allen D. Roses
Introduction 343
Drug Development Critical Path 344
Drug Development Economics 344
Methods for Identification of Genetic Classifiers 344
Pharmacogenomics in the Drug Development Pipeline 346
Efficacy Pharmacogenetics – here and Now 348
Drug Exposure Pharmacogenetics to Tune Efficacy and Safety Profiles 349
Investigation and Management of Safety in Clinical Trials 350
Other Genomic Methods: RNA Interference to Direct Drug Usage 352
“No Samples, No Science” 352
Conclusions 354
Acknowledgements 355
References 355
Section 5  Policy Challenges in Genomic and Personalized Medicine 387

33. From Sequence to Genomic Medicine: Genome Policy Considerations 388
   Susanne B. Haga
   Introduction 388
   Genome Research after the Human Genome Project 389
   Policy Issues in Large-scale Genetics and Genomics Research 391

Integrating Genomic Medicine Applications in Healthcare 392
Conclusion 396
References 397

34. Educational Strategies in Genomic Medicine 401
   Charles J. Epstein
   Introduction 401
   Genetic and Genomic Literacy of the Public and Makers of Public Policy 402
   Education of the Providers of Health Care 404
   Conclusion 411
   References 411

35. Federal Regulation of Genomic Medicine 414
   Janet Woodcock
   Introduction 414
   Regulation of Genomic Tests 416
   Pharmacogenomics in Drug Development And Clinical Medicine: the Role of Regulation 418
   Fda Efforts to Advance Genomic Product Development 421
   Conclusions 422
   References 422
   Recommended Resources 423

36. Economic Issues and Genomic Medicine 424
   David L. Veenstra, Louis P. Garrison and Scott D. Ramsey
   Introduction 424
   Economic Evaluation and Cost-effectiveness Analysis 424
   Evaluating Genomic Technologies 426
   Economic Incentives and the Future of Genomic Medicine 428
   Establishing Value-based Reimbursement For Genomic Technologies 430
   Conclusions 431
   References 432

37. Public–Private Interactions in Genomic Medicine: Research and Development 434
   Subhashini Chandrasekharan, Noah C. Perin, Ilse R. Wiechers and Robert Cook-Deegan
   Introduction 434
   Landscape of Private Sector Genomics 435
   Future Trends 441
   Acknowledgements 442
   References 442

Section 6  Genomic Medicine and Public Health 445

38. What Is Public Health Genomics? 446
   Alison Stewart and Ron Zimmern
   Introduction 446
   The Emergence of Public Health Genomics 446
   The Definition of Public Health Genomics 447
   Key Concepts in Public Health Genomics 447
**The “Enterprise” of Public Health Genomics**

The Continuum from Genetics to Genomics in Health Practice

**Core Activities in Public Health Genomics**

Moving Public Health Genomics Forward: Leadership and Networks

**Conclusion**

**References**

**Recommended Resources**

**40. Why Do We Need Public Health in the Era of Genomic Medicine?**

*Marta Gwinn and Muin J. Khoury*

**Introduction**

The Continuum from Genetics to Genomics in Health Practice

The Role of Public Health in the Translation of Human Genome Discoveries into Health Applications

The Focus on Disease Prevention and Health Promotion

The Population Perspective: Crucial Role of Public Health Sciences

The Role of Knowledge Integration Across Disciplines

The Role of Health Services Research and Population Health Assessment, Assurance, and Evaluation

**Conclusion**

**References**

**Recommended Resources**

**41. Principles of Human Genome Epidemiology**

*Marta Gwinn and Muin J. Khoury*

**Introduction**

Human Genome Epidemiology

Epidemiologic Study Designs

Epidemiologic Measures of Disease Frequency, Association, and Risk

Measurement and Bias

Gene–environment Interaction

Probability and Personalized Medicine

Building the Evidence Base

**Conclusion**

**References**

**Recommended Resources**

**42. Family History: A Bridge Between Genomic Medicine and Disease Prevention**

*Maren T. Scheuner and Paula W. Yoon*

**Introduction**

Clinical Approach

**Acknowledgements**

**References**

**Recommended Resources**

**Section 7 Clinical Technologies Supporting Personalized Medicine**

**43. Molecular Imaging as a Paradigm for Genomic and Personalized Medicine**

*Ralph Weissleder*

**Introduction**

Molecular Imaging and Cancer Detection

Molecular Imaging to Determine Treatment Efficacy

Molecular Imaging and Drug Development

Near-term Needs and Opportunities

**Acknowledgement**

**References**

**Recommended Resources**

**44. PET Imaging in Genomic Medicine**

*Vikas Kundra and Osama Mawlawi*

**Introduction**

**Physics**

Imaging Agents and Methods in Analysis of Biological Samples

**Conclusion**

**References**

**Recommended Resources**

**45. MRI for Molecular Imaging Applications: Overview, Perspectives, and Challenges**

*Dmitri Artemov*

**Introduction**

Basics of MRI Contrast

MR Contrast Agents for Molecular Imaging Applications

Molecular Imaging Applications of MRI

**Conclusions**

**Acknowledgements**

**References**

**Recommended Resources**

**46. Fluorescence Imaging: Overview and Applications in Biomedical Research**

*Vasili Ntziachristos*

**Introduction**

**Imaging Technology**

**References**

**Recommended Resources**
### 55. Lipoprotein Disorders

_Sekar Kathiresan and Daniel J. Rader_

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>634</td>
</tr>
<tr>
<td>Overview of Lipoprotein Metabolism</td>
<td>634</td>
</tr>
<tr>
<td>Plasma Lipid and Lipoprotein Levels and Atherosclerotic Cardiovascular Disease</td>
<td>636</td>
</tr>
<tr>
<td>Inherited Basis for Blood Lipid Traits</td>
<td>636</td>
</tr>
<tr>
<td>Screening for Lipid Disorders</td>
<td>637</td>
</tr>
<tr>
<td>Genetics of Ldl-c</td>
<td>637</td>
</tr>
<tr>
<td>Genetics of Hdl-c</td>
<td>639</td>
</tr>
<tr>
<td>Genetics of Triglycerides</td>
<td>642</td>
</tr>
<tr>
<td>Genetic Lipid Disorders Without Current Proven Molecular Etiology</td>
<td>643</td>
</tr>
<tr>
<td>Influence of Lipid-modulating Mutations on Risk of Atherosclerotic Cardiovascular Disease</td>
<td>643</td>
</tr>
<tr>
<td>Future Directions in Genetics And Genomics of Lipoproteins</td>
<td>644</td>
</tr>
<tr>
<td>Pharmacogenetics of Lipid-modulating Therapies</td>
<td>646</td>
</tr>
<tr>
<td>Implications of Genomics of Lipoprotein Metabolism For The Development of Novel Therapies</td>
<td>646</td>
</tr>
<tr>
<td>Clinical Recommendations for Genetic Testing for Lipid Disorders</td>
<td>647</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>648</td>
</tr>
<tr>
<td>References</td>
<td>648</td>
</tr>
<tr>
<td>Recommended Resources</td>
<td>651</td>
</tr>
</tbody>
</table>

### 56. Reactive Oxygen Species Signals Leading to Vascular Dysfunction and Atherosclerosis

_Nageswara R. Madamanchi, Aleksandr E. Vendrov and Marshall S. Runge_

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>652</td>
</tr>
<tr>
<td>Sources of ROS in vascular cells</td>
<td>652</td>
</tr>
<tr>
<td>Vascular Dysfunction and Atherosclerosis</td>
<td>653</td>
</tr>
<tr>
<td>ROS-induced inflammatory gene expression in vascular cells</td>
<td>653</td>
</tr>
<tr>
<td>Association of ROS modulators with atherosclerosis</td>
<td>654</td>
</tr>
<tr>
<td>ROS signaling in atherosclerotic risk factors</td>
<td>655</td>
</tr>
<tr>
<td>ROS-regulated signaling pathways</td>
<td>655</td>
</tr>
<tr>
<td>Regulation of transcription factors by ROS</td>
<td>656</td>
</tr>
<tr>
<td>ROS signaling in advanced atherosclerosis</td>
<td>658</td>
</tr>
<tr>
<td>Polymorphisms in ROS production genes and atherosclerosis</td>
<td>658</td>
</tr>
<tr>
<td>Inhibitors of ROS signaling and vascular disease</td>
<td>658</td>
</tr>
<tr>
<td>Conclusion</td>
<td>659</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>660</td>
</tr>
<tr>
<td>References</td>
<td>660</td>
</tr>
</tbody>
</table>

### 57. Genomics of Myocardial Infarction

_Carlos A. Hubbard and Eric J. Topol_

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>665</td>
</tr>
<tr>
<td>Predisposition</td>
<td>665</td>
</tr>
<tr>
<td>Screening Strategies</td>
<td>672</td>
</tr>
<tr>
<td>Diagnosis of Acute MI</td>
<td>673</td>
</tr>
<tr>
<td>Prognostic Implications of MI</td>
<td>673</td>
</tr>
<tr>
<td>Pharmacogenomics of MI</td>
<td>673</td>
</tr>
<tr>
<td>Novel and Emerging Therapies</td>
<td>674</td>
</tr>
<tr>
<td>Conclusion</td>
<td>675</td>
</tr>
<tr>
<td>References</td>
<td>676</td>
</tr>
<tr>
<td>Recommended Resources</td>
<td>679</td>
</tr>
</tbody>
</table>

### 58. Acute Coronary Syndromes

_L. Kristin Newby_

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>680</td>
</tr>
<tr>
<td>Predisposition</td>
<td>680</td>
</tr>
<tr>
<td>Screening</td>
<td>681</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>682</td>
</tr>
<tr>
<td>Prognosis</td>
<td>685</td>
</tr>
<tr>
<td>Pharmacogenomics</td>
<td>686</td>
</tr>
<tr>
<td>Monitoring</td>
<td>687</td>
</tr>
<tr>
<td>Novel and Emerging Therapies</td>
<td>687</td>
</tr>
<tr>
<td>Conclusion</td>
<td>687</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>688</td>
</tr>
<tr>
<td>References</td>
<td>688</td>
</tr>
<tr>
<td>Recommended Resources</td>
<td>690</td>
</tr>
</tbody>
</table>

### 59. Heart Failure in the Era of Genomic Medicine

_Ivor J. Benjamin and Jeetendra Patel_

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>692</td>
</tr>
<tr>
<td>Predisposition (Genetic and Non-genetic)</td>
<td>692</td>
</tr>
<tr>
<td>Screening</td>
<td>693</td>
</tr>
<tr>
<td>Pathophysiology</td>
<td>694</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>695</td>
</tr>
<tr>
<td>Prognosis</td>
<td>696</td>
</tr>
<tr>
<td>Pharmacogenomics</td>
<td>697</td>
</tr>
<tr>
<td>Monitoring</td>
<td>698</td>
</tr>
<tr>
<td>Novel Therapeutics and Future Directions</td>
<td>701</td>
</tr>
<tr>
<td>Conclusions and Recommendations</td>
<td>702</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>703</td>
</tr>
<tr>
<td>References</td>
<td>703</td>
</tr>
</tbody>
</table>

### 60. Application of Genomic Methodology for Assessment of Cardiac Transplant Rejection

_Michael Pham, Maria C. Deng, Jay Wohlgemuth and Thomas Quernerous_

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>705</td>
</tr>
<tr>
<td>Cardiac Allotransplantation as a Definitive Therapy for End-stage Heart Failure</td>
<td>705</td>
</tr>
<tr>
<td>The Problem of Allograft Rejection</td>
<td>706</td>
</tr>
<tr>
<td>Immunosuppression Strategies to Prevent Rejection</td>
<td>706</td>
</tr>
<tr>
<td>Current Strategies for Monitoring Transplant Rejection</td>
<td>707</td>
</tr>
</tbody>
</table>
61. Hypertrophic Cardiomyopathy in the Era of Genomic Medicine 716
   J. Martijn Bos, Steve R. Ommen and Michael J. Ackerman
   Introduction 716
   Definitions, Clinical Presentation, and Diagnosis 716
   Molecular Genetics of HCM 718
   Screening And Treatment for HCM 722
   Conclusions 725
   References 725

62. Genetics and Genomics of Arrhythmias 729
   Jeffrey A. Towbin and Matte Vatta
   Introduction 729
   Specific Cardiac Arrhythmias 729
   Primary Abnormalities in Cardiac Rhythm: Ventricular Tachyarrhythmias 729
   Complex Forms of Lqts 736
   Short Qt Interval Syndrome 741
   Familial Vt/cpvt 741
   Primary Conduction Abnormalities 742
   References 745

63. Hemostasis and Thrombosis 755
   Richard C. Becker and Felicita Andreotti
   Introduction 755
   Genetics of Coagulation 755
   Human Hemostatic Variability 756
   Genotype-phenotype Influences 757
   Gene-environment Influences on Hemostasis 758
   Circulating Cellular and Protein Influences on Hemostasis And Thrombosis 759
   Race-related Influences On Hemostasis and Thrombosis 760
   Linkage Studies in Thrombosis 762
   Association Studies in Thrombosis 762
   Heritability And Thrombosis: Existing Complexities 763
   A Personalized Approach to Hemostasis and Thrombosis 763
   Patient Screening: A Traditional Paradigm 764
   Patient Screening: A Comprehensive And Population-based Approach 767
   Prognostic Considerations 768
   Emerging Platform for Hemostasis and Thrombosis Research 768
   References 769

64. Peripheral Arterial Disease 773
   Ayotunde O. Dokun and Brian H. Annex
   Introduction 773
   Epidemiology and Risk Factors for PAD 773
   Clinical Manifestations of PAD 773
   Therapeutic Strategies for PAD 774
   Ic And Cli Are Distinct Clinical Outcomes of PAD 775
   Genetic Background as a Risk Factor for PAD 775
   Gene Polymorphisms Contributing to Atherosclerosis and PAD 775
   Polymorphisms in Pro-atherothrombotic Genes and PAD 776
   Genetic Locus Conferring Susceptibility to PAD 776
   Identification of Novel Gene Polymorphisms Involved in PAD 776
   Identification of a Quantitative Trait in a Preclinical Model of PAD 777
   Refining a QTL Using Haplotype Analysis 777
   Identification of Candidate Genes 777
   Future Potential Use of Genomic Methodologies in PAD 777
   Acknowledgements 778
   References 778

65. Genomics of Congenital Heart Disease 781
   Jessie H. Conta and Roger E. Breibart
   Introduction 781
   CHD Gene Discovery by Conventional Genetics 781
   Genomic Strategies for CHD Gene Discovery 786
   Cytogenetic and Molecular Genetic testing 787
   Medical Evaluation and Counseling Recommendations 788
   Conclusion 789
   Acknowledgements 790
   References 790

66. Genomics of Perioperative and Procedural Medicine 794
   Simon C. Body, Mihai V. Podgoreanu and Debra A. Schwinn
   Introduction 794
   Why Perioperative Insults are not Equivalent to Chronic Ambulatory Disease 795
### Section 9 Oncology Genomic Medicine

#### 67. Cancer Genes, Genomes, and the Environment

*Robert L. Strausberg*

- Introduction
- Acquired Functions of Cancer Cells
- Chromosomal Aberrations and Cancer
- Cancer Genes and their Functions
- Inherited Predisposition
- Cellular Progression Toward Cancer Through Somatic Changes
- From Genome to the Clinic
- Comprehensive Sequencing of the Kinome
- Expanding the Search
- Multiple Molecular Mechanisms for Oncogene Activation
- Microarrays and Cancer Genomics
- Environmental Cancer Genomics
- Cancer Genomic Databases Expedite Progress
- Mouse Models of Cancer
- Future Directions
- References

#### 68. Immune Cells and the Tumor Microenvironment

*David S. Hsu, Michael Morse, Timothy Clay, Gayathri Devi and H. Kim Lyerly*

- Introduction
- Immune Cells of the Tumor Microenvironment
- Examples of Tissue or Gene Microarrays used to Study Tumors
- Studies of Genomic Immune Stimulation within the Microenvironment
- Genomic Analysis of Tumor Microenvironment in Immunotherapy Studies
- Proteomics of Immune Cells and the Tumor Microenvironment
- Conclusion
- References

#### 69. Lymphomas

*Lisa Rimsza*

- Introduction
- Diffuse Large B-cell Lymphoma
- Primary Mediastinal Large B-cell Lymphoma
- Hodgkin Lymphoma
- Follicular Lymphoma
- Mantle Cell Lymphoma

#### 70. Genomics in Leukemias

*Lars Bullinger, Hartmut Dohner and Jonathan R. Pollack*

- Introduction
- Genomics in Leukemias—insights into Leukemia Biology
- Genomics in Leukemias—Evaluation of Drug Effects
- Genomics in Leukemias—Clinical Outcome Prediction
- Conclusions
- Acknowledgments
- References
- Recommended Resources

#### 71. Genomics of Lung Cancer

*Hasmeena Kathuria, Avrum Spira and Jerome Brody*

- Introduction
- Early Diagnosis/screening of Lung Cancer
- Classification And Prognosis
- Pathogenesis And Treatment of Lung Cancer
- Conclusion
- References
- Recommended Resource

#### 72. Breast Cancer and Genomic Medicine

*Erich S. Huang and Andrew T. Huang*

- Introduction
- The Promise
- Genetic Bases
- Molecular Bases
- Prognosis and Prediction
- Molecular Markers
- Genomic Insights
- Netherlands Cancer Institute Study
- Duke-taipei Study
- Nsabp Study
- Pathway Prediction
- The Reality of Clinical Genomics
- References

#### 73. Colorectal Cancer

*G.L. Wiesner, T.P. Slavin and J.S. Barnholtz-Sloan*

- Introduction
- Genomic Model of CRC
- Predisposition for CRC
- Risk Assessment, Evaluation, and Genetic Testing
- Screening and Surveillance
- Prognosis and Treatment
Diagnostic-therapeutic Combinations for Leukemia and Lymphoma 994
Her-2 Positive Breast Cancer and Trastuzumab (Herceptin®) 994
Other Targeted Anticancer Therapies Using Antibodies 995
Selected Targeted Anticancer Therapies Using Small Molecules 999
Pharmacogenomics 1002
Conclusion 1003
References 1003

Section 10 Inflammatory Disease Genomic Medicine 1009

83. Environmental Exposures and the Emerging Field of Environmental Genomics 1010
David A. Schwartz
Introduction 1010
Importance of Environmental Exposures in Human Health 1010
Importance of Environmental Exposures in Studying Disease Processes 1012
Comparative Environmental Genomics 1012
Exposure Assessment in the Gene-environment Paradigm 1013
Challenges and Future of Environmental Genomics 1015
Conclusion 1015
References 1015

84. Molecular Basis of Rheumatoid Arthritis 1017
Robert M. Plenge and Michael E. Weinblatt
Introduction 1017
Clinical Features 1018
Predisposition 1018
Screening 1024
Diagnosis, Prognosis, and Monitoring 1024
Pharmacogenomics 1024
Conclusions 1026
References 1026

85. “Omics” in the Study of Multiple Sclerosis 1032
Francisco J. Quintana and Howard L. Weiner
Introduction 1032
Genomics in MS 1032
Transcriptomics in MS 1034
Immunomics in MS 1035
Proteomics in MS 1036
Conclusion 1037
References 1037

86. Inflammatory Bowel Disease 1040
Ad A. van Bodegraven and Cisca Wijmenga
Introduction 1040
Predisposition (Genetic and Non-genetic) 1041

Screening 1043
Diagnosis 1044
Prognosis 1045
Pharmacogenomics 1047
Monitoring 1047
Novel and Emerging Therapeutics 1048
Conclusions 1049
References 1050

87. Glomerular Disorders 1056
Tadashi Yamamoto, Hidehiko Fujinaka and Visith Thongboonkerd
Introduction 1056
Techniques for Detection, Quantification, and Profiling of mRNA Expression in the Kidney 1056
mRNA Expression Profiles of Glomerular Disorders 1059
Genome Variations in Glomerular Disorders 1060
Genetics of Congenital Glomerular Disorders 1062
Genomic Medicine for Glomerular Disorders 1062
Conclusions 1064
References 1064

88. Spondyloarthropathies 1067
Dirk Elewaut, Filip De Keyser, Filip Van den Bosch, Dieter Deforce and Herman Mielants
Introduction 1067
Characteristics of SPA 1067
Role of Bowel Inflammation 1070
Histopathology of Synovitis in SPA 1072
Gut and Synovium Transcriptomes 1074
Proteome Analysis 1075
Novel and Emerging Therapeutics and Biomarkers 1075
Conclusions 1077
References 1078

89. Asthma Genomics 1084
Scott T. Weiss, Benjamin A. Raby and Juan C. Celedón
Introduction 1084
Asthma: Basic Pathobiology 1084
Predisposition (Genetic and Non-genetic) to Asthma 1085
Genome-wide Linkage Analyses of Asthma and its Intermediate Phenotypes 1085
Candidate-gene Association Studies of Asthma 1087
Genome-wide Association Studies of Asthma 1088
Asthma Genomics 1088
Screening 1088
Diagnosis 1091
Prognosis 1091
Pharmacogenetics 1091
Monitoring 1092
Novel and Emerging Therapeutics 1093
Conclusions 1093
Acknowledgements 1093
References 1093
Recommended Resources 1097
90. Genomic Aspects of Chronic Obstructive Pulmonary Disease 1098
Peter J. Barnes
Introduction 1098
Predisposition 1098
Pathophysiology 1099
Cellular and Molecular Mechanisms 1101
Diagnosis and Screening 1104
Prognosis 1105
Management 1105
New Treatments 1107
Conclusions 1107
References 1108

91. Genomic Determinants of Interstitial Lung Disease 1110
P.W. Noble and M.P. Steele
Introduction 1110
Genetic Determinants of DpId in Mouse Strains 1111
Genetic Determinants of Sarcoidosis 1111
Surfactant Proteins and DpId 1114
Genetic Determinants of Pulmonary Fibrosis Identified in Rare Inherited Disorders 1115
Genetic Determinants of Pif 1115
Conclusion 1117
References 1118

92. Peptic Ulcer Disease 1122
J. Holton
Introduction 1122
Clinical and Physiological Aspects of Pud 1123
Pathophysiology of Ulcer Formation 1124
The Helicobacter Genome 1125
Human Polymorphism and Pud 1130
Genomics in the Management of Disease 1131
Future Developments in the use of Genomic Techniques in Relation to Pud 1132
Conclusions 1132
Acknowledgements 1133
References 1133
Recommended Resources 1137

93. Cirrhosis in the Era of Genomic Medicine 1138
N.A. Shackel, K. Patel and J. McHutchison
Introduction 1138
Liver Structure 1138
Fibrosis and Cirrhosis 1140
Diagnosis of Cirrhosis 1140
Treatment of Cirrhosis 1141
Genetics of Cirrhosis 1142
The Liver Transcriptome 1143
The Liver Proteome 1143
Development of Liver Fibrosis 1144
Transcriptome Analysis of Liver Disease 1146
Proteomic Studies of Liver Disease 1148
Proteomics in Other Liver Disease 1150
Future Impact of Genomics Studies 1151
Conclusion 1151
References 1151

94. Systemic Sclerosis 1155
Ulf Müller-Ladner
Introduction 1155
Predisposition 1155
Screening 1158
Diagnosis 1159
Prognosis 1159
Pharmacogenomics 1159
Monitoring and Genomic Factors 1159
Therapeutic Strategies 1162
Novel and Emerging Therapeutics 1164
Conclusions 1165
Acknowledgements 1165
References 1165

Section II Metabolic Disease Genomic Medicine 1169

95. Genomic Medicine of Obesity 1170
J. Alfredo Martínez
Introduction 1170
Obesity: Causes and Genetic Predisposition 1170
Search of Genes Involved in Obesity 1172
Diagnosis and Characterization of Genes Associated with Obesity 1175
Screening and Diagnosis 1179
Prognosis and Gene Based-treatments 1180
Novel and Emerging Therapeutics Nutrigenomics, Pharmacogenomics and Gene Therapy 1182
Conclusions 1183
Acknowledgements 1183
References 1184

96. Diabetes 1187
Maggie Ng and Nancy J. Cox
Introduction 1187
GWAS in Type 2 Diabetes 1188
Future Research in Type 2 Diabetes Genetics 1190
GWAS in Type 1 Diabetes 1191
Future Studies in Type 1 Diabetes 1192
Clinical Utility of Genetic Research in Diabetes 1192
Conclusion 1192
References 1192

97. Metabolic Syndrome 1194
Rebecca L. Pollex and Robert A. Hegele
Introduction 1194
Diagnosis: Definition of the MetS Phenotype 1194
Pathophysiology of MetS in Brief 1196
Genetics of MetS 1196
## Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conclusion</td>
<td>1200</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>1200</td>
</tr>
<tr>
<td>References</td>
<td>1200</td>
</tr>
<tr>
<td>Recommended Resources</td>
<td>1202</td>
</tr>
<tr>
<td>98. Nutrition and Diet in the Era of Genomics</td>
<td>1204</td>
</tr>
<tr>
<td>Jose M. Ordovas and Dolores Corella</td>
<td></td>
</tr>
<tr>
<td>Introduction</td>
<td>1204</td>
</tr>
<tr>
<td>Methodological Issues</td>
<td>1205</td>
</tr>
<tr>
<td>Gene–Nutrient Interactions</td>
<td>1206</td>
</tr>
<tr>
<td>Path Forward</td>
<td>1214</td>
</tr>
<tr>
<td>Conclusions</td>
<td>1214</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>1215</td>
</tr>
<tr>
<td>References</td>
<td>1215</td>
</tr>
<tr>
<td>103. Genomic Basis of Neuromuscular Disorders</td>
<td>1265</td>
</tr>
<tr>
<td>Erynn S. Gordon and Eric P. Hoffman</td>
<td></td>
</tr>
<tr>
<td>Introduction</td>
<td>1265</td>
</tr>
<tr>
<td>Motor Neuron Disease</td>
<td>1265</td>
</tr>
<tr>
<td>Disorders of the Neuromuscular Junction</td>
<td>1266</td>
</tr>
<tr>
<td>Disorders of the Muscle</td>
<td>1268</td>
</tr>
<tr>
<td>Predisposition</td>
<td>1268</td>
</tr>
<tr>
<td>Screening</td>
<td>1273</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>1274</td>
</tr>
<tr>
<td>Prognosis</td>
<td>1274</td>
</tr>
<tr>
<td>Monitoring</td>
<td>1275</td>
</tr>
<tr>
<td>Current, Novel, and Emerging Therapies</td>
<td>1276</td>
</tr>
<tr>
<td>Advances in Genomics and Proteomics</td>
<td>1277</td>
</tr>
<tr>
<td>Conclusion</td>
<td>1279</td>
</tr>
<tr>
<td>References</td>
<td>1279</td>
</tr>
<tr>
<td>Recommended Resources</td>
<td>1281</td>
</tr>
<tr>
<td>104. Psychiatric Disorders</td>
<td>1282</td>
</tr>
<tr>
<td>Stephan Züchner and Ranga Krishnan</td>
<td></td>
</tr>
<tr>
<td>Introduction</td>
<td>1282</td>
</tr>
<tr>
<td>Great Prospect, But are We There Yet?</td>
<td>1282</td>
</tr>
<tr>
<td>Classification Reconsidered</td>
<td>1283</td>
</tr>
<tr>
<td>How Complex Can it Be?</td>
<td>1283</td>
</tr>
<tr>
<td>The Value of Rare Genetic Variation</td>
<td>1284</td>
</tr>
<tr>
<td>Converging Methods</td>
<td>1284</td>
</tr>
<tr>
<td>Personalized Medicine</td>
<td>1285</td>
</tr>
<tr>
<td>Conclusion</td>
<td>1286</td>
</tr>
<tr>
<td>References</td>
<td>1287</td>
</tr>
<tr>
<td>105. Genomics and Depression</td>
<td>1289</td>
</tr>
<tr>
<td>Brigitta Bondy</td>
<td></td>
</tr>
<tr>
<td>Introduction</td>
<td>1289</td>
</tr>
<tr>
<td>Diagnosis, Prevalence and Course of Depression</td>
<td>1289</td>
</tr>
<tr>
<td>Pathophysiological Mechanisms</td>
<td>1290</td>
</tr>
<tr>
<td>Pharmacogenomics of Antidepressants</td>
<td>1293</td>
</tr>
<tr>
<td>Current Concepts</td>
<td>1294</td>
</tr>
<tr>
<td>Future Aspects</td>
<td>1296</td>
</tr>
<tr>
<td>References</td>
<td>1296</td>
</tr>
<tr>
<td>106. Bipolar Disorder in the Era of Genomic Psychiatry</td>
<td>1299</td>
</tr>
<tr>
<td>Ayman H. Fanous, Frank Middleton, Carlos N. Pato and Michele T. Pato</td>
<td></td>
</tr>
<tr>
<td>Introduction</td>
<td>1299</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>1299</td>
</tr>
<tr>
<td>Predisposition</td>
<td>1300</td>
</tr>
<tr>
<td>Pharmacogenetics</td>
<td>1304</td>
</tr>
<tr>
<td>Section 13 Infectious Disease Genomic Medicine</td>
<td>1313</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>107. Genomic Approaches to the Host Response to Pathogens</td>
<td>1314</td>
</tr>
<tr>
<td><em>M. Frances Shannon</em></td>
<td></td>
</tr>
<tr>
<td>Introduction</td>
<td>1314</td>
</tr>
<tr>
<td>Genetic Susceptibility to Pathogens</td>
<td>1315</td>
</tr>
<tr>
<td>Exploring the Host Response Through Expression Profiling</td>
<td>1317</td>
</tr>
<tr>
<td>Genetical Genomics and Systems Biology: the New Frontiers</td>
<td>1320</td>
</tr>
<tr>
<td>Application to Clinical Practice</td>
<td>1320</td>
</tr>
<tr>
<td>Acknowledgement</td>
<td>1320</td>
</tr>
<tr>
<td>References</td>
<td>1320</td>
</tr>
<tr>
<td>Recommended Resources</td>
<td>1323</td>
</tr>
<tr>
<td>108. Genomic Medicine and AIDS</td>
<td>1324</td>
</tr>
<tr>
<td><em>Thomas Hirtzig, Yves Lévy and Jean-François Zagury</em></td>
<td></td>
</tr>
<tr>
<td>Introduction</td>
<td>1324</td>
</tr>
<tr>
<td>Context of HIV and AIDS</td>
<td>1324</td>
</tr>
<tr>
<td>Predisposition: Susceptibility to HIV-1 Infection</td>
<td>1328</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>1328</td>
</tr>
<tr>
<td>Prognosis</td>
<td>1329</td>
</tr>
<tr>
<td>Monitoring</td>
<td>1331</td>
</tr>
<tr>
<td>Pharmacogenomics</td>
<td>1331</td>
</tr>
<tr>
<td>Novel and Emerging Therapeutics</td>
<td>1333</td>
</tr>
<tr>
<td>Conclusion</td>
<td>1334</td>
</tr>
<tr>
<td>References</td>
<td>1334</td>
</tr>
<tr>
<td>109. Viral Genomics and Antiviral Drug</td>
<td>1340</td>
</tr>
<tr>
<td><em>Roberto Patarca</em></td>
<td></td>
</tr>
<tr>
<td>Introduction</td>
<td>1340</td>
</tr>
<tr>
<td>Viral Genomics and the Antiviral Drug Revolution Era</td>
<td>1341</td>
</tr>
<tr>
<td>Conclusion</td>
<td>1344</td>
</tr>
<tr>
<td>References</td>
<td>1345</td>
</tr>
<tr>
<td>110. Host Genomics and Bacterial Infections</td>
<td>1347</td>
</tr>
<tr>
<td><em>Melissa D. Johnson and Mihai Netea</em></td>
<td></td>
</tr>
<tr>
<td>Introduction</td>
<td>1347</td>
</tr>
<tr>
<td>Genomics and the Study of Bacterial Infections</td>
<td>1347</td>
</tr>
<tr>
<td>Host Genomics and Gram-positive, Gram-negative and Mycobacterial Infections</td>
<td>1351</td>
</tr>
<tr>
<td>Future Directions</td>
<td>1357</td>
</tr>
<tr>
<td>Conclusions</td>
<td>1357</td>
</tr>
<tr>
<td>References</td>
<td>1357</td>
</tr>
<tr>
<td>111. Sepsis and the Genomic Revolution</td>
<td>1362</td>
</tr>
<tr>
<td><em>Christopher W. Woods, Robert J. Feezor and Stephen F. Kingsmore</em></td>
<td></td>
</tr>
<tr>
<td>Introduction</td>
<td>1362</td>
</tr>
<tr>
<td>Genetic Polymorphisms Associated with Sepsis</td>
<td>1363</td>
</tr>
<tr>
<td>Molecular Signatures and Sepsis</td>
<td>1368</td>
</tr>
<tr>
<td>Therapeutics</td>
<td>1371</td>
</tr>
<tr>
<td>Conclusion</td>
<td>1371</td>
</tr>
<tr>
<td>References</td>
<td>1372</td>
</tr>
<tr>
<td>112. Diagnosis, Management and Disease Mechanisms of Hepatitis in the Era of Genomic Medicine</td>
<td>1375</td>
</tr>
<tr>
<td><em>N.A. Shackel, K. Patel and J. McHutchison</em></td>
<td></td>
</tr>
<tr>
<td>Introduction</td>
<td>1375</td>
</tr>
<tr>
<td>Virology of Hepatitis Viruses</td>
<td>1375</td>
</tr>
<tr>
<td>Acquisition and Predisposition to Viral Hepatitis</td>
<td>1377</td>
</tr>
<tr>
<td>Screening and Diagnosis of Viral Hepatitis</td>
<td>1378</td>
</tr>
<tr>
<td>Pathogenesis of Viral Hepatitis</td>
<td>1380</td>
</tr>
<tr>
<td>Therapeutics and Pharmacogenomics</td>
<td>1384</td>
</tr>
<tr>
<td>Future Impact of Genomics Studies</td>
<td>1386</td>
</tr>
<tr>
<td>Conclusion</td>
<td>1386</td>
</tr>
<tr>
<td>References</td>
<td>1386</td>
</tr>
<tr>
<td>Glossary</td>
<td>1391</td>
</tr>
<tr>
<td>Index</td>
<td>1407</td>
</tr>
</tbody>
</table>